Brief: Arch Biopartners Receives Approval From Turkish Ministry Of Health To Proceed With Phase II Trial For Lsalt Peptide
07/10/2020 13:21
Oct 7 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS RECEIVES APPROVAL FROM TURKISH MINISTRY
OF
HEALTH TO PROCEED WITH PHASE II TRIAL FOR LSALT PEPTIDE; BEGINS
SCREENING PATIENTS IN FLORIDA
* ARCH BIOPARTNERS - ACTIVATION OF CLINICAL SITES IN
ISTANBUL AND
ANKARA AND PATIENT ENROLLMENT INTO PHASE II TRIAL WILL BEGIN
IMMINENTLY IN TURKEY
* ARCH BIOPARTNERS INC - CONTINUES TO PREPARE ACTIVATION OF
TWO
ADDITIONAL U.S. SITES INTO PHASE II TRIAL
Source text for Eikon: ID:nGNX16hZs6
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide